HomeCompareNSBTX vs JNJ

NSBTX vs JNJ: Dividend Comparison 2026

NSBTX yields 0.46% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NSBTX wins by $292.00 in total portfolio value
10 years
NSBTX
NSBTX
● Live price
0.46%
Share price
$6.76
Annual div
$0.03
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.3K
Annual income
$47.25
Full NSBTX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — NSBTX vs JNJ

📍 NSBTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNSBTXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NSBTX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NSBTX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NSBTX
Annual income on $10K today (after 15% tax)
$38.98/yr
After 10yr DRIP, annual income (after tax)
$40.16/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $663.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NSBTX + JNJ for your $10,000?

NSBTX: 50%JNJ: 50%
100% JNJ50/50100% NSBTX
Portfolio after 10yr
$20.2K
Annual income
$437.51/yr
Blended yield
2.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NSBTX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NSBTX buys
0
JNJ buys
0
No recent congressional trades found for NSBTX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNSBTXJNJ
Forward yield0.46%3.36%
Annual dividend / share$0.03$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$20.3K$20.0K
Annual income after 10y$47.25$827.78
Total dividends collected$466.00$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NSBTX vs JNJ ($10,000, DRIP)

YearNSBTX PortfolioNSBTX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,746$45.86$10,676$355.77+$70.00NSBTX
2$11,544$46.05$11,407$389.39+$137.00NSBTX
3$12,398$46.24$12,198$426.53+$200.00NSBTX
4$13,313$46.41$13,056$467.62+$257.00NSBTX
5$14,291$46.57$13,987$513.12+$304.00NSBTX
6$15,338$46.73$14,998$563.56+$340.00NSBTX
7$16,459$46.87$16,098$619.52+$361.00NSBTX
8$17,658$47.00$17,295$681.69+$363.00NSBTX
9$18,941$47.13$18,599$750.82+$342.00NSBTX
10$20,314$47.25$20,022$827.78+$292.00NSBTX

NSBTX vs JNJ: Complete Analysis 2026

NSBTXStock

The investment seeks the highest available current income consistent with liquidity and low risk to principal; total return is a secondary goal. To pursue its goals, the fund invests mainly in investment-grade bonds and other debt securities issued by domestic and foreign governments, corporate entities, and trusts. It normally invests at least 80% of its net assets in bonds and other debt securities and other investment companies that provide investment exposure to such debt securities.

Full NSBTX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this NSBTX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NSBTX vs SCHDNSBTX vs JEPINSBTX vs ONSBTX vs KONSBTX vs MAINNSBTX vs ABBVNSBTX vs MRKNSBTX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.